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Abstract
Background
In age-related macular degeneration (AMD) the complement system is thought to be acti-
vated by chronic oxidative damage with genetic variants identified in the alternative pathway
as susceptibility factors. However, the involvement of the lectin pathway of complement, a
key mediator of oxidative damage, is controversial. This study investigated whether man-
nose-binding lectin (MBL) levels and genetic variants in lectin pathway proteins, are associ-
ated with the predisposition to and severity of AMD.
Methods
MBL levels and single nucleotide polymorphisms (SNPs) in theMBL2 and the ficolin-2
(FCN2) gene were determined in 109 patients with AMD and 109 age- and sex-matched
controls.
Results
MBL expression levels were equally distributed in both cases (early and late AMD) and con-
trols (p>0.05). However, there was a trend towards higher median MBL levels in cases with
late AMD compared to cases with early AMD (1.0 vs. 0.4 μg/ml, p = 0.09) and MBL defi-
ciency (<0.5 μg/ml) was encountered less frequently in the late AMD group (35% vs 56%,
p = 0.03). FCN2 andMBL2 allele frequencies were similarly distributed in early and late
AMD cases compared with controls (p>0.05 for all analyses) as wereMBL2 genotypes.
PLOS ONE | DOI:10.1371/journal.pone.0134107 July 24, 2015 1 / 11
OPEN ACCESS
Citation: Osthoff M, Dean MM, Baird PN, Richardson
AJ, Daniell M, Guymer RH, et al. (2015) Association
Study of Mannose-Binding Lectin Levels and Genetic
Variants in Lectin Pathway Proteins with Susceptibility
to Age-Related Macular Degeneration: A Case-
Control Study. PLoS ONE 10(7): e0134107.
doi:10.1371/journal.pone.0134107
Editor: James D. Chalmers, University of Dundee,
UNITED KINGDOM
Received: May 12, 2015
Accepted: July 6, 2015
Published: July 24, 2015
Copyright: © 2015 Osthoff et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Similarly, there was no significant difference in allele frequencies in any SNPs in either the
MBL2 or FCN2 gene in cases with early vs. late AMD.
Conclusions
SNPs of lectin pathway proteins investigated in this study were not associated with AMD or
AMD severity. However, MBL levels deserve further study in a larger cohort of early vs. late
AMD patients to elucidate any real effect on AMD severity.
Introduction
Age-related macular degeneration (AMD) is the leading cause of progressive loss of central
vision and ultimately severe vision impairment in the elderly population of developed coun-
tries. With the overall ageing of the population, its prevalence is expected to increase by at least
50% in the next 10 years [1]. Approximately 30% of persons over 75 years of age have some
signs of AMD, and about 6% of persons in this age group suffer from the most advanced forms
of AMD [2]. The early stage of the disease is characterized by a thickening of Bruch’s mem-
brane and accumulation of deposits in the central retina (macula), beneath the retinal pigment
epithelium (RPE), called drusen. Ongoing deposition and subsequent inflammation result in
two advanced forms: geographic atrophy (dry AMD) with loss of RPE and photoreceptors, and
choroidal neovascularisation (wet AMD) with leaking choroidal vessels invading the retina,
both leading to an irreversible loss of central vision without treatment [3].
Both genetic and environmental factors (e.g. smoking and diet) have been implicated in this
complex disease (reviewed in [4]). Regarding genetics, dysregulated local complement activa-
tion and subsequent chronic inflammation are considered to play an essential role in the patho-
genesis of AMD (reviewed in [2]). Indeed, genome-wide and targeted linkage studies have
identified several components of the complement system as major susceptibility loci for the
development of AMD [5–7]. Besides a strong genetic association of mutations in the regula-
tory/inhibitory proteins of the alternative pathway (complement factor H and B, and Factor H-
like protein) with AMD there is also evidence demonstrating an involvement of several other
components of the complement system (e.g. C2, C3, complement factor H related proteins),
that either intensify complement attacks, slow complement activation, or alter other control
proteins, in addition to molecules from the cholesterol and angiogenesis pathway [4,8]. Hence,
the genetic complexity of AMD is much greater than initially thought. Additionally, certain
pathogens (like Chlamydia pneumoniae or Cytomegalovirus) have been implicated in the path-
ogenesis of AMD (by inducing a chronic inflammatory state) [9,10] and in AMD disease pro-
gression when in the presence of the CC risk genotype of the single nucleotide polymorphism
(SNP) rs1061170 (Y402H) [11].
Although the current understanding of the pathogenesis of AMD is that chronic oxidative
damage over time perpetuates a chronic inflammatory state via activation of the complement
cascade, it remains to be determined which tissue ligands trigger complement activation and
which components of the complement system are actually responsible for the damage.
Activation of the complement cascade is possible via one of three pathways, the classical,
the lectin, and the alternative pathway, the latter one having a crucial role in amplifying com-
plement activation. The lectin pathway is activated after binding of mannose-binding lectin
(MBL) or ficolins (ficolin-1, -2, and -3) to pathogens or dying cells with subsequent activation
of MBL-associated serine protease-1 and -2 and assembly of the C3 convertase [12]. Inter-
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individual serum concentrations of these pattern recognition receptors vary to a certain degree
with MBL showing the greatest range (from undetectable to about 10 ug/ml) [13]. Well charac-
terized polymorphisms in the exon and promoter region of theMBL2 gene on chromosome 10
are responsible for the remarkable variations in serumMBL concentration in healthy individu-
als [14]. Notably, almost a third of the population worldwide display moderate to severe MBL
deficiency[14]. Similarly, a number of major polymorphisms have been described for the fico-
lin-2 gene (FCN2) with a much weaker genotypic/phenotypic relationship than is the case for
MBL [15]. Both MBL and ficolins have been shown to be involved in the binding and removal
of certain pathogens and dying cells leading to complement activation in an antibody- and
complement C1q independent manner [16–19]. Hence, MBL deficiency and/or low ficolin lev-
els might lead to an impaired clearance of apoptotic debris or certain pathogens in AMD and
consequently to sustained inflammation with activation of other complement pathways. How-
ever, a recent study has identified an antithetical involvement of the lectin pathway in AMD. In
an in vitromodel of oxidatively stressed RPE cells, the lectin pathway was found to be crucial
in triggering activation of the complement cascade after binding to natural IgM antibodies
bound to neoepitopes with subsequent amplification via the alternative pathway, whereas the
classical pathways was not involved [20]. Comparable data in human AMD are scarce and
essentially limited to a single study by Dinu V. et al., which identified a single nucleotide poly-
morphisms in theMBL2 gene locus in a focused, pathway-based (instead of a genome-wide)
association study, that was associated with an increased risk to develop wet AMD[21]. Given
the potential involvement of the lectin pathway in the pathogenesis of AMD and the limited
evidence from previous human studies we investigated the role of two lectin pathway pattern
recognition receptors, MBL and ficolin-2, in the predisposition to AMD in a case-control
study.
Patients and Methods
Ethics Statement
This matched case-control study was approved by both the Melbourne Health and the Royal
Victorian Eye and Ear Hospital Human Research and Ethics Committees and all participants
gave written informed consent for the study.
Participants
136 individuals with AMD were recruited at the Centre for Eye Research Australia and 132
individuals with a similar age range but without evidence of AMD were recruited either at the
Centre for Eye Research Australia or at the Royal Melbourne Hospital cataract surgery clinics.
Subsequently, AMD cases and controls were matched for age (within 5 years) and sex, yielding
a cohort of 109 participants in each group for primary analyses.
AMD detection and definition
Digital non-stereoscopic fundus photography of the macular and optic disc was performed and
graded in all subjects as described previously [22]. Participants were categorized on the status
of the worse affected eye. Controls demonstrated bilateral normal fundi without evidence of
drusen of any size. Exclusion criteria for both groups included: glaucoma, significant cataracts,
any corneal pathology that could compromise vision, diabetes, uncontrolled hypertension,
amblyopia, neurological or systemic disease affecting vision or any medication known to affect
the retina. All cases with the early stages of AMD had intermediate AMD with the presence of
drusen> 125 μm, with or without the presence of pigmentary abnormalities. Evidence of
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choroidal neovascularization (CNV), geographic atrophy or a disciform scar qualified for a
diagnosis of late AMD [23].
Definition of endpoints
The main aim of this exploratory study was to compare the frequency of MBL deficiency
(defined as serumMBL levels< 0.5 μg/ml) in cases and controls [24]. As genetic material was
available in the same subjects associations ofMBL2 and FCN2 SNPs with AMD susceptibility
and severity were investigated.
Determination of MBL plasma levels
Quantification of serumMBL levels was performed by an investigator blinded to any patient
data using a mannan-binding enzyme-linked immunosorbent assay as previously described
[25]. Briefly, mannan-coated microtitre plates were incubated with samples at 1:25 and 1:100
dilutions for 90 min at room temperature followed by detection of bound MBL with a biotiny-
lated monoclonal anti-MBL antibody (HYB 131–01, BioPorto Diagnostics, Denmark). After
incubation with ExtrAvidin peroxidase conjugate (Sigma-Aldrich, Australia), plates were
developed with TMB substrate solutions (BD OptEIA, BD Biosciences, Australia), stopped
with 1 M H2SO4 (Sigma-Aldrich, Australia) and read immediately on a Bio-Rad plate reader
(Bio-Rad, Australia). MBL levels were calculated against a standard pool serum (BioPorto
Diagnostics, Denmark). MBL deficiency was defined as serum level< 0.5 μg/ml and, severe
as< 0.1 μg/ml, respectively [26].
MBL2 and ficolin-2 genotyping
MBL2 and FCN2 promoter and exon SNPs were determined by allele specific polymerase
chain reaction (PCR) using TaqMan fluorescent probes (TaqMan genotyping assays, Life
Technologies, Australia). For assay details, see S1 Table. Stored genomic DNA was used for all
cases and all controls recruited at the Centre for Eye Research Australia. For controls recruited
at the Royal Melbourne Hospital, DNA lysates were prepared from 2μl of stored buffy coat
according to the manufacturer’s instruction (TaqMan Sample-to-SNP, Life Technologies, Aus-
tralia), and stored genomic DNA was used for all cases. For all TaqMan assays, DNA amplifica-
tion was carried out in 5μL volume reactions containing 1μl of DNA lysate or 20ng of genomic
DNA, 0.25μl TaqMan genotyping assay mix, 2.5μl TaqMan GTXpress Master Mix (Life Tech-
nologies, Australia) and 1.25μl DNase-free water. All reactions were performed in 384-well
plates and in the ViiA 7 thermocycler (Life Technologies, Australia) according to the manufac-
turer’s instructions. For allelic discrimination end-point fluorescence was read at 25°C, and the
ViiA 7 software was used to analyze the results (Life Technologies, Australia).
MBL2 SNPs were chosen on the basis of their remarkable impact on MBL levels compared
to other promoter or exon polymorphisms.MBL2 genotypes were classified as low (XA/YO,
YO/YO), intermediate (XA/XA, YA/YO) or high (YA/YA, XA/YA) producing genotypes
according to published literature [24] with exon 1 variant alleles (rs1800450 (codon 54),
rs1800451 (codon 57) or rs5030737 (codon 52)) collectively designated as O and the wild-type
allele as A, and the promoter variant and the wild-type allele (rs7096206 (-221 X/Y)) desig-
nated as X and Y, respectively. Common FCN2 promoter and exon SNPs were analyzed sepa-
rately and combined as haplotype [27].
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Statistical analysis
This study sample was powered to detect an increase in the frequency of MBL deficiency
(defined as MBL serum levels< 0.5 μg/ml) by a factor of 2.3 in AMD cases similar to the study
of C3 polymorphisms and AMD susceptibility [28] with an expected frequency of MBL defi-
ciency in the control population of 25% at the 5% level of significance.
To investigate MBL and ficolin-2 as potential risk factors for AMD, matched univariate
analysis was performed by running conditional logistic regression on one variable at a time
with AMD as the dependent variable. In addition, Wilcoxon signed-rank test was applied to
compare MBL levels in cases and matched controls. Haplotype frequencies were analyzed by
expectation-maximum algorithm.
We used Pearson's chi-square test for comparisons of categorical variables and allele and
genotype frequencies and to check for Hardy–Weinberg equilibrium. For AMD severity analy-
sis MBL levels were analyzed using the Mann-Whitney-U-Test. All testing was two-tailed.
Haplotype and linkage disequilibrium analysis was carried out with the Haploview program
(version 4.2). All other analyses were performed using SPSS statistics, version 17.0 (SPSS Inc.,
USA).
Results
Baseline characteristics
136 cases and 132 controls were genotyped for theMBL and FCN2 genes. After matching for
age and gender, the final study population consisted of 109 cases and controls. The mean age
(standard deviation) was 76.2 (8.7) years in cases and 75.0 (8.1) in controls with 62.4% being
female in both groups. Cases comprised 34 (31%) patients with neovascular AMD in their
worst eye, 20 (18%) patients with geographic atrophy in their worst eye, and 55 (51%) patients
with signs of the early stages of AMD had intermediate AMD in their worst eye. Two individu-
als did not have a final grading but were deemed to have AMD at some level. Controls had no
signs of AMD on retinal photography.
Cases and controls were all successfully genotyped at 4 loci in theMBL2 gene and 6 loci in
the FCN2 gene, and allele frequencies at all positions were in agreement with the predicted
Hardy-Weinberg equilibrium (S1 Table) (p>0.05). As expected median, MBL levels signifi-
cantly correlated withMBL2 genotypes (<0.001 (interquartile range (IQR) 0–0.001) for low
(XA/YO, YO/YO), 0.3 (IQR 0.2–0.8) for intermediate (XA/XA, YA/YO), and 1.6 (1.0–2.4) for
high (YA/YA, XA/YA) producingMBL2 genotypes, p<0.001).
MBL and ficolin-2 and age-related macular degeneration
Median MBL levels were similar in cases and controls (0.7 (IQR 0.2–1.6) vs. 0.7 (IQR 0.1–1.7)
μg/ml, respectively, p = 0.9) as was the frequency of moderate and severe MBL deficiency (46
vs. 43%, respectively, p = 0.7 and 19 vs. 23%, respectively, p = 0.5).
Frequencies ofMBL2 exon or promoter variant alleles and genotypes did not differ
significantly between AMD cases (early and late) and controls (Table 1). Similarly, FCN2 hap-
lotypes and variant alleles were equally distributed with the exception of the variant haplotype
AGAGTG (−986G> A, −602G>A, −557A>G, −4A>G +6359 C>T and +6424 G>T), which
was less frequently observed in cases (Table 2). When cases with advanced AMD, i.e. neovascu-
lar or geographic atrophy, were grouped together and compared with controls, none of the loci
were found to be significant at the p = 0.05 level (data not shown). Comparison of the interme-
diate AMD cases with controls also demonstrated that none of the loci at either gene were sig-
nificant at the p = 0.05 level (data not shown).
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With regards to AMD severity there was no significant difference inMBL2 allele and FCN2
allele or haplotype frequencies in cases with early vs. late AMD (data not shown). However,
there was a trend towards higher MBL levels in cases with late AMD compared to participants
with early AMD changes (1.0 (IQR 0.3–1.9) vs. 0.4 (IQR 0.1–1.4) μg/ml, p = 0.09), and MBL
deficiency (<0.5 μg/ml) was encountered less frequently in the late AMD group (19 (35%) vs
31 (56%), p = 0.03).
Overall, the above results were similar when analyzing the entire, unmatched cohort of 136
cases and 132 controls (data not shown).
Discussion
The lectin pathway of complement has been implicated in the pathogenesis of AMD in several
experimental models [20,29,30]. This is the first human study designed to examine the role of
two lectin pathway pattern recognition molecules, MBL and ficolin-2, in the predisposition to
and severity of AMD, exclusively.
Table 1. Analysis of MBL levels andMBL2 polymorphisms in AMD cases and controls.
Variables Cases Controls Univariate matched analysis
(n = 109) (n = 109) OR (95% CI) P value
MBL2 exon variants, n (%)
rs1800451 (Codon 57)
G/G 102 (94) 105 (96) Reference
G/A 7 (6) 5 (4) 1.75 (0.51–5.98) 0.37
A/A - - - -
rs1800450 (Codon 54)
G/G 79 (72) 81 (74) Reference
G/A 28 (26) 25 (23) 1.12 (0.61–2.07) 0.7
A/A 2 (2) 3 (3) 0.72 (0.12–4.44) 0.7
rs5030737 (Codon 52)
C/C 89 (82) 86 (79) Reference
C/T 19 (17) 20 (18) 0.93 (0.45–1.93) 0.9
T/T 1 (1) 3 (3) 0.33 (0.04–3.21) 0.3
MBL2 promoter variant, n (%)
rs7096206 (-221, Y/X)
G/G 69 (63) 63 (58) Reference
G/C 37 (34) 40 (37) 0.84 (0.49–1.46) 0.5
C/C 3 (3) 6 (5) 0.46 (0.11–1.90) 0.3
MBL2 genotypes, n (%)
high producing 53 (49) 53 (49) Reference
intermediate producing 38 (35) 31 (28) 1.28 (0.63–2.60) 0.5
low producing 18 (16) 25 (23) 0.76 (0.37–1.58) 0.5
MBL levels (μg/ml), median (IRQ) 0.74 (0.17–1.56) 0.72 (0.12–1.69) 0.99 (0.78–1.27) 1.0
MBL <0.5μg/ml, n (%) (46) (43) 1.13 (0.65–1.98) 0.7
MBL <0.1 μg/ml, n (%) (19) (23) 0.81 (0.43–1.53) 0.5
MBL2 genotypes were classified as low (XA/YO, YO/YO), intermediate (XA/XA, YA/YO) or high (YA/YA, XA/YA) producing genotypes with exon variant
alleles (codon 57, 54 and 52) collectively designated as O and the wild-type allele as A, and the promoter variant and the wild-type allele designated as X
and Y, respectively. Abbreviations: CI, confidence interval; MBL, mannose-binding lectin; OR, odds ratio; IQR, interquartile range; Y and A denote MBL2
promoter and exon wildtype alleles, respectively.
doi:10.1371/journal.pone.0134107.t001
MBL/Ficolin-2 and Age-Related Macular Degeneration
PLOS ONE | DOI:10.1371/journal.pone.0134107 July 24, 2015 6 / 11
Despite previous experimental studies that were the basis for our a priori hypotheses, we did
not demonstrate any relevant associations of SNPs in theMBL2 or FCN2 gene or MBL protein
levels with the early stages or late AMD in our matched case-control study. Similarly,MBL2
and FCN-2 polymorphisms had no influence on the severity of AMD in our cohort.
However, there was a non-significant trend towards higher MBL levels in cases with late
AMD compared to early AMD corresponding to a significantly lower frequency of MBL
deficiency.
This is in contrast to a complement pathway-focused association study by Dinu V et al.,
who identified a SNP in the intron region of theMBL2 gene as being able to differentiate
between early and late AMD [21]. TheMBL2 SNP identified in that study as being associated
with AMD severity has neither been shown to influence serumMBL levels nor associate with
Table 2. Analysis of FCN2 polymorphisms in AMD cases and controls.
Variables Cases Controls Univariate matched analysis
(n = 109) (n = 109) OR (95% CI) P value
FCN2–986, n (%)
G/G 26 (24) 23 (21) Reference
G/A 53 (49) 52 (48) 0.90 (0.44–1.83) 0.8
A/A 30 (27) 34 (31) 0.81 (0.40–1.63) 0.6
FCN2–602, n (%)
G/G 63 (58) 65 (60) Reference
G/A 41 (38) 40 (37) 1.06 (0.61–1.86) 0.8
A/A 5 (4) 4 (3) 1.28 (0.34–4.89) 0.7
FCN2–557, n (%)
A/A 83 (76) 82 (75) Reference
A/G 26 (24) 23 (21) 1.05 (0.56–1.97) 0.9
G/Ga 0 (0) 4 (4) 0.11 (<0.01–1.05) 0.1
FCN2–4, n (%)
A/A 63 (58) 53 (49) Reference
A/G 41 (38) 44 (40) 0.77 (0.43–1.36) 0.4
G/G 5 (4) 12 (11) 0.37 (0.13–1.09) 0.1
FCN2 + 6359, n (%)
C/C 60 (55) 48 (44) Reference
C/T 44 (40) 48 (44) 0.72 (0.41–1.27) 0.3
T/T 5 (5) 13 (12) 0.32 (0.11–0.95) 0.04
FCN2 + 6424, n (%)
G/G 88 (81) 83 (76) Reference
G/T 21 (19) 22 (20) 0.90 (0.48–1.70) 0.8
T/Ta 0 (0) 4 (4) 0.10 (<0.01–1.01) 0.1
Haplotypes (−986/−602/-557/−4/+6359/+6424), n (%)
GGAACG 39 (36) 34 (31) Reference
AGAGTG 24 (22) 34 (31) 0.57 (0.35–0.93) 0.02
AAAACG 24 (22) 21 (19) 0.98 (0.59–1.63) 0.9
GGGACT 10 (9) 13 (12) 0.56 (0.30–1.05) 0.07
AGAACG 6 (6) 2 (2) 2.14 (0.68–6.73) 0.2
Abbreviations: CI, confidence interval; OR, odds ratio
a Exact logistic regression was used to compute OR, CI and p value.
doi:10.1371/journal.pone.0134107.t002
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other diseases such as colon cancer or breast cancer [31,32]. For these reasons we did not
screen for this SNP in our cohort.
In addition, two experimental studies have demonstrated that the lectin pathway is at least
partly responsible for complement activation in AMD in vitro and rodent models [20,29]. In
the study by Joseph K et al., MBL and ficolins (mainly ficolin-1 and -3) were shown to be capa-
ble of activating the lectin pathway of complement after binding to natural antibodies attached
to oxidatively stressed RPE cells with the alternative pathway acting as an amplification loop
[20].
Several reasons might account for our inability to find an association of MBL deficiency
and/orMBL2/FCN2 polymorphisms in the present study. First, the lectin pathway, and MBL
and ficolin-2 in particular, might indeed not be involved in the pathogenesis of AMD. This is
supported by several genome-wide association studies that have not found a significant associ-
ation in the region of those two genes [5,33,34]. Second, AMD is a complex disease with multi-
ple environmental and genetic factors involved. Hence, previous in vitro and rodent models
that have demonstrated a role of the lectin pathway in AMD, might not have been able to
account for the complexity of human AMD. Third, our study was only powered to detect a
2.3-fold difference in the frequency of MBL deficiency defined as serum levels< 0.5 μg/ml
(which was more frequent in controls than expected). Our negative result and insufficient
power influenced our decision to not include other important genetic and environmental fac-
tors in our analysis for controls recruited at one site. This may have biased our results. SNPs
involving the lectin pathway might still have some influence in AMD risk but at a lower fre-
quency than that which we were powered to detect. It is still important to search for these rare
haplotypes as they may provide important information about pathways and mechanisms
involved in AMD pathogenesis [35],[36,37].
In this regard, a trend for higher MBL levels and a significantly lower frequency of MBL
deficiency in the late AMD group is of interest. This finding was contrary to our hypothesis but
might be worth exploring in larger cohorts as experimental studies have suggested that comple-
ment activation initiated by the lectin pathway potentiates retinal damage [20,29]. There is
clearly plentiful evidence to suggest the involvement of the complement system in the patho-
genesis of AMD. However, the exact mechanism of involvement remains to be elucidated.
Limitations of our study include the sample size, in particular of advanced cases of AMD
and the absence of phenotypic ficolin-2 testing in our cohort. Although there is a significant
correlation of FCN2 genotypes with ficolin-2 serum levels, the ability of FCN2 genotyping to
predict serum concentrations is limited [15]. Hence, we cannot exclude an influence of ficolin-
2 at the phenotypic level in AMD given that the variant FCN2 haplotype AGAGTG was less
common in AMD cases. In addition, we limited our analysis to two pattern recognition recep-
tors of the lectin pathway. Ideally, future AMD association studies should include other impor-
tant lectin pathway proteins like ficolin-1 and -3 and MASP-1 and -2. We were not able to
match for important environmental risk factors like smoking in our study which might have
biased our results. We were not able to provide data on the activation state of the complement
system in cases and controls which could influenced MBL levels[38].
In conclusion, we were not able to find any evidence from our matched case-control study
to support a relevant role for SNPs in either theMBL2 or FCN2 genes in the predisposition to
and severity of AMD. We have not excluded a rarer association with AMD. Due to our obser-
vation of lower MBL levels in less severe AMD cases future studies are needed to validate this
association and determine if indeed the lectin pathway of complement is ultimately involved in
the pathogenesis of AMD.
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